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Abstract: Dogs develop osteosarcoma (OSA) and the disease process closely resembles that of human
OSA. OSA has a poor prognosis in both species and disease-free intervals and cure rates have not
improved in recent years. Gene expression in canine OSAs was compared with non-tumor tissue
utilising RNA sequencing, validated by qRT-PCR and immunohistochemistry (n = 16). Polymorphic
polyglutamine (polyQ) tracts in the androgen receptor (AR/NR3C4) and nuclear receptor coactivator 3
(NCOA3) genes were investigated in control and OSA patients using polymerase chain reaction (PCR),
Sanger sequencing and fragment analysis (n = 1019 Rottweilers, 379 Irish Wolfhounds). Our analysis
identified 1281 significantly differentially expressed genes (>2 fold change, p < 0.05), specifically 839
lower and 442 elevated gene expression in osteosarcoma (n = 3) samples relative to non-malignant
(n = 4) bone. Enriched pathways and gene ontologies were identified, which provide insight into
the molecular pathways implicated in canine OSA. Expression of a subset of these genes (SLC2A1,
DKK3, MMP3, POSTN, RBP4, ASPN) was validated by qRTPCR and immunohistochemistry (MMP3,
DKK3, SLC2A1) respectively. While little variation was found in the NCOA3 polyQ tract, greater
variation was present in both polyQ tracts in the AR, but no significant associations in length were
made with OSA. The data provides novel insights into the molecular mechanisms of OSA in high
risk breeds. This knowledge may inform development of new prevention strategies and treatments
for OSA in dogs and supports utilising spontaneous OSA in dogs to improve understanding of the
disease in people.
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1. Introduction
Osteosarcoma (OSA) is a rare cancer that typically affects adolescents and the elderly [1],
and survival rates for OSA have seen little improvement in more than 20 years [2,3]. One challenge to
the development of improved treatments for OSA in people is the limitation of relevant models. Animal
models of OSA rely on chemical induction, xeno/allografts, and genetically engineered animals that do
not fully reflect aspects of spontaneously occurring disease [4–7]. Canine OSA occurs spontaneously
and is believed to share similarities with human OSA [4]. Published incidence rates are 27.2 dogs and
0.89 people per 100,000 population [8,9]. Aside from potentially improving the understanding of OSA
in people, canine OSA is a significant veterinary clinical challenge in its own right. One-year survival
rates following diagnosis and treatment are typically lower than 45% [10–12].
Risk factors for people developing OSA include sex, race, puberty, and growth [3,13,14]. Canine
OSA typically affects large and giant breeds, with Irish Wolfhounds (IWH), Rottweilers, Scottish
Deerhounds, St Bernards, and Great Danes particularly affected [9], reflecting the human population
where individuals with OSA are more likely to be taller than average [9,14,15]. In the canine population,
as with human populations, there also appears to be a skewed sex ratio with males more likely to
develop OSA than females [1,9]. Neutering status, although less relevant in the human context,
also appears to contribute to OSA risk, where neutered dogs are more likely to develop OSA than those
that remain entire [16]. This, combined with the association with puberty, suggests a complex role for
sex hormone signalling in OSA risk.
The androgen receptor (AR/NR3C4) is a member of the ligand-dependent superfamily of
transcription factors [17–20]. In the presence of an agonist, the AR recruits many epigenetic coregulators
to mediate transcriptional regulation [21]. Notable examples of coregulators include the p160
coactivators, NCOA1, NCOA2 and NCOA3 [21]. The AR gene is X-linked, with both males and females
possessing functional AR, however, differing levels of circulating androgens between the sexes result
in different receptor activation [22]. Mutations in the AR gene can alter the sensitivity of the receptor to
androgens [23,24]. Some AR mutations cause complete androgen insensitivity where genetically 46XY
males appear to be phenotypically female [18,23,25,26]. In addition to loss of function AR mutations,
there is a polymorphic polyglutamine (polyQ) tract within the AR gene that shows variation in the
polyQ repeat number [27,28]. The variation in AR gene polyQ repeats has been associated with prostate
cancer, breast cancer, ovarian hyperandrogenism, and Kennedy’s disease [29–33]. Individuals with
shorter polyQ tracts are more sensitive to androgens, while individuals with longer polyQ tracts are
less sensitive [27,28]. Androgen activation of the AR requires the presence of coactivators [34–37].
One such coactivator, NCOA3, also harbours a polyQ repeat [38,39]. Expression of NCOA3 has been
associated with increased AR activation in prostate cancer and urothelial carcinoma of the bladder
in humans [35,37]. In addition, increased expression of NCOA3, with implications for AR activation,
and variation in the length of the polyQ repeat in the NCOA3 gene have been associated with bone
cancer, epithelial ovarian cancer, colorectal cancer, and breast cancer in humans [40–43]. The polyQ
tract within the AR and NCOA3 genes has not been investigated in relation to canine OSA.
Although OSA itself does not generally appear to be heritable, the risk factors themselves have
heritable components [44]. To date there have been no external modifiable risk factors identified in the
development of OSA outside of individuals with inherited cancer syndromes, where radiation has
been identified as a factor in tumor development [45,46]. In people, some rare heritable syndromes
have been found to increase the risk of developing OSA [47–49]. The lack of identified modifiable risk
factors limits the development of effective OSA prevention strategies, thus to date the emphasis has
been placed on the development of early diagnostic and improved treatment approaches to advance
OSA outcomes in people. Over 900 genes are associated with human OSA [50], but only two somatic
genetic mutations have been specifically associated with OSA [13]. This lack of identified genetic
associations is not surprising considering the lack of heritability observed in human OSA. Genomic
and chromosomal instability is a reported factor in many types of cancer progression [51,52], and OSA
has been shown to display chromosomal instability associated with mutations in the TP53 gene [53].
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A consequence of this chromosomal instability is aneuploidy, which can lead to the overexpression of
some genes within malignant cells, disrupting normal cell processes [54]. Although mutations in TP53
appear to be associated with chromosomal instability, the gene itself does not seem to be subsequently
over expressed following aneuploidy [53,54].
In contrast to human OSA, canine OSA may be heritable, with an apparent predisposition in some
breeds [9,55]. Interestingly, of the 15 breeds with the highest reported incidence of OSA, 12 are within
a unique clade on the canine phylogenetic tree [9,56]. This relationship between affected breeds could
indicate a potential common genetic origin of canine OSA; however, the clade is large and also contains
many breeds that do not commonly develop OSA [56]. There have been 34 genetic loci associated with
canine OSA across four breeds [57,58]. None of the loci are consistently associated across breeds, further
suggesting that there may be a difference between breeds in the genetic predisposition to developing
canine OSA [57,58]. Currently none of the genetic variants identified as associated with canine OSA
have had their mechanism of action verified. Differentially expressed genes between canine OSA and
non-tumor tissue have been identified that have implications for growth and metastasis, are potential
drug targets [59–62], and are associated with survival time [63–66]. Additional work is required to
confirm the effect of the genetic loci identified as associated with canine OSA, and to account for
the variation observed in the development of disease between breeds [57,58]. The Irish Wolfhound
(IWH) breed has the highest prevalence of OSA [9] with one of the lower median ages of onset at
6.6 years [9], with four loci associated with OSA development [58]. The IWH is closely related to the
Scottish Deerhound as the latter breed was used to re-establish the breed in the early 1860s through
to the 1930s [67]. Scottish Deerhounds are a minority breed and therefore do not commonly appear
on incidence breed lists, but OSA is a common problem within this breed with an incidence rate of
more than 15%, double that of the general canine population [16,55]. Heritability has been estimated at
0.69; both dominant and recessive models have been suggested [55,68]. One study has shown linkage
between OSA and chromosome 34q16.2–17.1; a region syntenic to human chromosome 3q26, which is
also associated with OSA incidence [57]. Rottweilers have the fifth highest incidence ranking for OSA
with a median age of onset of 7.9 years [9] and 15 OSA associated loci [58].
Improving OSA survival rates will only be possible with additional understanding of the
disease and the development of novel treatments and drugs targeting OSA-specific pathways [69–71].
The present study used next generation RNA sequencing to identify novel differentially expressed
genes in OSA tumor tissue as compared to matched non-tumor tissue and assessed NCOA3 and AR
polyQ tract variations in affected and non-affected IWH and Rottweiler dogs.
2. Results
2.1. RNAseq Gene Expression
The Illumina iGenomes CanFam3.1 Ensembl (Illumina, San Diego, CA, USA) annotated genome
comprising 24,580 genes was included in the RNAseq analysis. Of these genes, 1281 were identified
with a fold change of ≥2 between tumor and non-tumor tissue and a p < 0.05 (n = 4 non-tumor
and n = 3 tumor samples). Higher expression of 442 genes and lower expression of 839 genes was
observed in tumor tissue compared to the non-tumor tissue (Figure 1A,B, Tables 1 and 2, and Table S1).
The biological relevance of these significantly differentially expressed genes was analysed using
over-representation of enriched pathways, gene ontologies and predicted transcription factor networks
using the WebGestalt platform (http://www.webgestalt.org/, Zhang Lab, Baylor College of Medicine,
Houston, TX, USA; Tables S2 and S3). Differentially expressed genes were significantly associated with
pathways associated with heme biosynthesis, calcium homeostasis and signalling (Tables 2 and 3).
Significantly enriched gene ontologies and enriched predicted transcription factor networks were also
identified (Tables S2 and S3).
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Figure 1. Differentially expressed genes were identified in OSA relative to non-malignant bone. RNA 
sequencing was used to identify differentially expressed genes expressed lower (green) and higher 
(red) in OSA tumor specimens relative to non-malignant bone specimens. A volcano plot (A) and 
unsupervised hierarchical clustering was used to display the identified differentially expressed 
genes (B). 
2.2. qRT-PCR and Immunohistochemistry Validation 
Validation of seven differentially expressed genes identified by RNAseq was performed by 
qRT-PCR analysis of eight non-malignant bone specimens and seven OSA specimens. Expression for 
MMP3 (t = 4.884, p < 0.0001), SLC2A1 (t = 3.703, p = 0.0006), DDK3 (t = 3.981, p = 0.0003), POSTN (t = 
2.061, p = 0.0455), RBP4 (t = 3.048, p = 0.004) and ASPN (t = 2.733, p = 0.0091) was confirmed to be 
higher in the tumor tissues (Figure 2A–G). Differential expression of S100A8 was not confirmed by 
qRT-PCR (t = 1.766 p = 0.0847; Figure 2H). Immunostaining confirmed positive expression of MMP3, 
SLC2A1 and DKK3 proteins in OSA tissue (Figure 3). 
Figure 1. Differentially xpressed genes were identified in OSA relative to no lignant bone.
RNA sequencing was used to i entify differentially expressed genes expressed lower (green)
higher (red) in OSA tumor specimens relative to non-malignant bone specimens. A volcano plot
(A) and unsupervised hierarchical clustering was used to display the identified differentially expressed
genes (B).
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Table 1. Top 25 genes expressed lower in osteosarcoma relative to non-malignant bone.
Gene_ID Gene Log2 Fold Change p Value
ENSCAFG00000007134 MYBPC1 −14.4441 0.01395
ENSCAFG00000001705 MB −13.3627 0.0081
ENSCAFG00000013875 MYL1 −13.1689 0.00085
ENSCAFG00000008253 ACTA1 −12.3844 0.003
ENSCAFG00000011103 NRAP −12.1537 0.00015
ENSCAFG00000005717 ENSCAFG00000005717 −12.0616 0.00035
ENSCAFG00000014281 PYGM −11.6411 0.0057
ENSCAFG00000011619 MYH7 −11.4064 0.0001
ENSCAFG00000002620 TNNT1 −11.3052 0.0119
ENSCAFG00000001016 TRDN −11.034 0.0005
ENSCAFG00000009333 CESDD1 −10.7269 0.04655
ENSCAFG00000005896 RYR1 −9.83487 0.01135
ENSCAFG00000009404 TNNC1 −9.61599 0.0317
ENSCAFG00000015475 DES −9.54008 0.0062
ENSCAFG00000005358 HHATL −9.49779 0.0023
ENSCAFG00000008707 CKMT2 −9.43202 0.00015
ENSCAFG00000017254 ATP2A1 −9.34349 0.01225
ENSCAFG00000001140 MYOT −9.08389 0.0191
ENSCAFG00000012927 ALPK3 −9.01117 0.0005
ENSCAFG00000005343 KLHL40 −8.96012 0.0234
ENSCAFG00000002982 MYBPC2 −8.66855 0.01675
ENSCAFG00000012432 MYOZ2 −8.62006 0.00415
ENSCAFG00000011638 SPTA1 −8.56014 0.00135
ENSCAFG00000001161 OBSCN −8.44333 0.01045
ENSCAFG00000011418 HFE2 −8.31185 0.0051
RNA sequencing was used to identified differentially expressed genes in OSA (osteosarcoma) specimens relative to
non-malignant bone. The entire list of 1281 differentially expressed genes is reported in Table S1.
Table 2. Top 25 genes expressed higher in osteosarcoma relative to non-malignant bone.
Gene_ID Gene Log2 Fold Change p Value
ENSCAFG00000010484 PKP2 3.54183 0.00095
ENSCAFG00000005510 EOMES 3.56165 0.04155
ENSCAFG00000012983 GPR64 3.66911 0.0009
ENSCAFG00000013448 COLGALT2 3.69448 0.0007
ENSCAFG00000007845 DKK3 3.76815 0.0013
ENSCAFG00000009722 TOX3 3.77935 0.0002
ENSCAFG00000023615 MMP-12 3.78547 0.0001
ENSCAFG00000002589 COL9A1 3.84351 0.0001
ENSCAFG00000003503 ARHGEF5 3.84945 0.0006
ENSCAFG00000005101 RPSA 3.86821 0.00135
ENSCAFG00000019918 FOXF1 3.8936 0.0005
ENSCAFG00000017309 RPL4 3.92678 0.00015
ENSCAFG00000018123 ARSI 3.92752 0.0004
ENSCAFG00000007280 RNF180 4.12335 0.00015
ENSCAFG00000010205 ID4 4.12517 0.0108
ENSCAFG00000006073 POSTN 4.15174 0.03365
ENSCAFG00000009756 ELOVL2 4.23619 0.00035
ENSCAFG00000002307 ASPN 4.25607 0.02175
ENSCAFG00000009135 SAA1 4.42549 0.0053
ENSCAFG00000019036 LIPG 4.44654 0.0061
ENSCAFG00000016731 MSX2 4.46357 0.0337
ENSCAFG00000015063 MMP3 4.56236 0.0337
ENSCAFG00000018597 LAMA1 4.58776 0.00025
ENSCAFG00000029131 HAPLN1 4.61072 0.00015
ENSCAFG00000031443 EREG 5.61347 0.02875
RNA sequencing was used to identified differentially expressed genes in OSA specimens relative to non-malignant
bone. The entire list of 1281 differentially expressed genes is reported in Table S1. Expressions of MMP3, ASPN,
DKK3, and POSTN were validated using qRT-PCR.
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Table 3. KEGG, Panther and Reactome pathway analysis identified as significantly (q < 0.05) enriched in
the dataset. Differentially expressed genes associated with canine OSA were used in a comparative search
of the human KEGG, Panther and Reactome pathway databases to identify over-represented pathways.
Gene Set Database Description Size Expect Ratio False DiscoveryRate (FDR)
hsa05414 KEGG Dilatedcardiomyopathy 90 5.9888 2.6717 0.04748
hsa05410 KEGG Hypertrophiccardiomyopathy 83 5.523 2.7159 0.04748
hsa04020 KEGG Calcium signalingpathway 183 12.177 2.053 0.04748
P02746 Panther Hemebiosynthesis 12 0.96911 7.2231 0.001603
R-HSA-397014 Reactome Musclecontraction 206 13.605 2.7932 0.0075
R-HSA-189451 Reactome Hemebiosynthesis 11 0.72645 11.012 0.00
R-HSA-390522 Reactome Striated MuscleContraction 36 2.3775 5.468 0.000151
R-HSA-189445 Reactome Metabolism ofporphyrins 17 1.1227 8.0164 0.00017
R-HSA-109582 Reactome Hemostasis 620 40.946 1.6363 0.014273
R-HSA-5578775 Reactome Ion homeostasis 56 3.6983 3.5151 0.018011
R-HSA-5576891 Reactome Cardiacconduction 141 9.3118 2.3626 0.037904
2.2. qRT-PCR and Immunohistochemistry Validation
Validation of seven differentially expressed genes identified by RNAseq was performed by
qRT-PCR analysis of eight non-malignant bone specimens and seven OSA specimens. Expression for
MMP3 (t = 4.884, p < 0.0001), SLC2A1 (t = 3.703, p = 0.0006), DDK3 (t = 3.981, p = 0.0003), POSTN
(t = 2.061, p = 0.0455), RBP4 (t = 3.048, p = 0.004) and ASPN (t = 2.733, p = 0.0091) was confirmed to be
higher in the tumor tissues (Figure 2A–G). Differential expression of S100A8 was not confirmed by
qRT-PCR (t = 1.766 p = 0.0847; Figure 2H). Immunostaining confirmed positive expression of MMP3,
SLC2A1 and DKK3 proteins in OSA tissue (Figure 3).
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and DKK3 (G,H) in osteosarcoma tissue (n = 16). Scale bar represents 50 µm (E,G) and 100 µm 
(A–D,F,H). 
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entire Nottingham cohort inclusive of dogs of all ages. Significant differences were identified in the 
age at OSA diagnosis between males and females in both breeds. Mean age at OSA diagnosis for 
male IWHs was 5.34 years, whereas in females this was 7.65 years (t = 3.04, p = 0.0069). A similar 
difference in the age at diagnosis was observed in Rottweilers, with a mean age at diagnosis for 
males of 7.00 years while that for females was 8.50 years (t = 2.34, p = 0.027, summarised in Table 4). 
There were no differences between the sexes in the proportion of individuals affected by OSA in 
IWHs—χ2test result = 0.065 (p = 0.80), or Rottweilers—χ2test result = 0.17 (p = 0.68). 
Figure 2. qRT-PCR validation of RNA expression co paring osteosarcoma tumor tissue expression
with non-tumor bone tissue expression. Differential expression of key genes was identified by RNAseq
(A). Results from MMP3, SLC2A1, DKK3, POSTN, RBP4, and ASPN (B–H) were consistent with the
RNAseq results, however, no significant differences were observed in S100A8 (H). Significance levels
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = not significant.
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Figure 3. Protein expression of P3, SLC2A1, and DKK3 in osteosarcoma tumor. Negative control
im unohistochemistry tissues received no pri ary antibody and were incubated in fetal calf serum
instead (A,B). Im unohistoc e istr c fir ed protein expression of MP3 (C,D), SLC2A1 (E,F),
and DK 3 (G,H) in osteosarco a ti 16). Scale ba repr sents 50 µm (E,G) and 100 µm
(A–D,F,H).
2.3. Cohort Epidemiology
From the buccal swab cohort, 12 I s (8 fe ales and 4 males) and 31 Rottweilers (19 females
and 12 males) were reported it i osed by veterinary surgeons and reported by owners),
repres nting 0.53% of all IWHs (fro ) nd 3.04% of Rottweilers (from n = 1019) within the
entire Nottingham cohort inclusi f l ages. Sign ficant diff rences were identified in the
age at OSA diagnosis between males and females in both breeds. Mean age at OSA diagnosis for male
IWHs was 5.34 years, whereas in females this was 7.65 years (t = 3.04, p = 0.0069). A similar difference
in the age at diagnosis was observed in Rottweilers, with a mean age at diagnosis for males of 7.00 years
while that for females was 8.50 years (t = 2.34, p = 0.027, summarised in Table 4). There were no
differences between the sexes in the proportion of individuals affected by OSA in IWHs—χ2test result
= 0.065 (p = 0.80), or Rottweilers—χ2test result = 0.17 (p = 0.68).
Table 4. Breed and sex ages at diagnosis.
OSA Cases and Diagnosis IWH (n = 379) Rottweiler (n = 1019)
Number of OSA cases (%) 0.53 3.04
Male age of diagnosis (mean, years) 5.34 7.65
Female age of diagnosis (mean, years) 7.00 ** 8.50 *
* p > 0.05 ** p > 0.01. No significant difference between number of affected males and females in each breed.
Of IWH males, 80% that developed OSA had done so before the age of 6.5 years, while 80%
of IWH females that developed OSA had done so by 9 years. Rottweilers tend to live longer than
IWHs, therefore a 90% threshold was used to determine the age restrictions in this breed. Of male
Rottweilers, 90% of those that developed OSA were diagnosed before the age of 9 years, whereas
90% of OSA-affected females were diagnosed before the age of 10 years. Using these age restrictions,
there were 23 male IWHs unaffected by OSA over 6.5 years and 6 female IWHs unaffected by OSA
over 9 years from the cohort of 379. There were 51 male Rottweilers unaffected by OSA over the age
of 9 years and 53 female Rottweilers unaffected by OSA over 10 years old from the cohort of 1019.
These individuals were used as control samples for polyQ tract analysis (summarized in Table 5).
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Table 5. Number of AR polyglutamine (polyQ) repeats in IWHs and Rottweilers in OSA/non OSA
males and females.
Breed Group Diagnosis and Age AR1 Q-Repeat AR2 Q-Repeat AR Q-Repeat Number(Mean ± SEM)
IWH Male OSA 10.25 ± 0.25 (4) 24.50 ± 0.29 (4) 34.75 ± 0.25 (4)
Non OSA over 6.5 years 10.05 ± 0.05 (19) 24.31 ± 0.12 (16) 34.31 ± 0.12 (16)
Female OSA 10.13 ± 0.13 (8) 24.57 ± 0.13 (7) 34.57 ± 0.13 (7)
Non OSA over 9 years 10.04 ± 0.04 (13) 24.19 ± 0.16 (13) 34.23 ± 0.15 (13)
Rottweiler Male OSA 11.00 ± 0.00 (12) 23.00 ± 0.00 (12) 34.00 ± 0.00 (12)
Non OSA over 9 years 11.00 ± 0.00 (49) 23.00 ± 0.00 (50) 34.00 ± 0.00 (49)
Female OSA 11.03 ± 0.03 (19) 23.00 ± 0.00 (18) 34.03 ± 0.03 (18)
Non OSA over 10 years 11.00 ± 0.00 (43) 22.98 ± 0.02 (45) 34.00 ± 0.00 (43)
Numbers represent mean ± SEM (number of samples), OSA = osteosarcoma.
2.4. Androgen polyQ Analysis
Across all individuals genotyped at both AR1 and AR2, the total length of the AR polyQ tract
ranged from 33 to 35 repeats. The length of the AR1 polyQ tract ranged from 10 to 12 repeats and the
length of the AR2 polyQ tract ranged from 23 to 25 repeats (Figure 4). NCOA3 had a range of 15 to
16 repeats within the polyQ tract across all genotyped individuals (Figure 4). There were no significant
differences in mean AR polyQ repeat length between IWHs (t = 2.04, p = 0.053) or Rottweilers (t = 1.00,
p = 0.33) with and without a diagnosis of OSA. When individuals were split by sex there remained
no significant differences between groups (IWH OSA: ANOVA—F = 1.28, p = 0.30; Rottweiler OSA:
ANOVA—F = 1.88, p = 0.14, Table 5). Similar results were obtained when AR1 and AR2 were considered
separately. There were also no significant differences in AR1 or AR2 length between individuals with
and without OSA in IWHs (AR1 t = 1.02, p = 0.33; AR2 t = 1.83, p = 0.08) and Rottweilers (AR1 t = 1.00,
p = 0.33; AR2 t = 1.00, p = 0.32). The length of AR1 or AR2 did not differ significantly when sex was
compared in IWHs (AR1 F = 0.80, p = 0.50; AR2 F = 1.04, p = 0.39; Table 5) or Rottweilers (AR1 F = 1.88,
p = 0.14; AR2 F = 0.55, p = 0.65; Table 5).
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There were no significant differences in mean NCOA3 polyQ repeat length between IWHs with a
diagnosis of OSA and IWHs included in the unaffected by OSA group, as all individuals had 15 repeats
in their polyQ tract. There were two IWH individuals in the study that had 16 repeats; these individuals
were unaffected by OSA but had not yet reached the age restrictions to be included in the unaffected
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group analysis. Similarly, there was little variation in the NCOA3 polyQ repeat length in Rottweilers
with two individuals in the unaffected by OSA group having a mean repeat length of 15.5. The resulting
t-test was not significant (t = 1.42, p = 0.16).
Analysis of the frequencies of the entire populations demonstrated significant differences in AR1
and AR2 polyQ repeat frequencies between the two breeds (AR1 χ2test result = 1707, p = < 0.00001;
AR2 χ2test result = 1687; p = <0.00001). IWHs had fewer repeats at AR1, but more repeats at AR2,
compared to Rottweilers (4). The mean repeat length overall of AR was significantly increased in
IWHs at 34.25 (range 33–35.5) repeats in comparison to Rottweilers at 34.02 (range 33–35; t-test,
t = 10.62, p = <0.0001). There was no significant difference between breeds in the NCOA3 polyQ repeat
frequencies, χ2test result = 1.79, (p = 0.18).
3. Discussion
Differential gene expression in cancers has been associated with disease progression and
prognosis [70,72–74]. This study identified 583 genes as differentially expressed between canine
OSA (n = 3) and non-tumor (n = 5) bone tissue by RNAseq analysis (Figure 1). Many of these genes
had previously been identified as differentially expressed in other cancers and could be potential drug
targets in the treatment of OSA. qRT-PCR was used to validate RNAseq results for MMP3 SLC2A1,
DKK3, POSTN, RBP4, and ASPN (Figure 2). Separately we used immunohistochemistry to confirm
protein expression and localisation of MMP3, SLC2A1 and DKK3 in bone and OSA specimens (Figure 3).
The MMP3 gene encodes a member of the matrix metalloproteinase proteins, which degrades
a range of extracellular matrix components and is therefore an important mediator of metastatic
invasion [75,76]. High MMP3 protein expression has been shown in breast, lung, and pancreatic cancer,
and has been associated with poor prognosis [77]. In addition, MMP3 expression in the murine model
of mammary carcinoma has been demonstrated to be important for primary tumor and metastasis
growth [78]. Formation of metastases in OSA is a critical stage in disease progression associated with
poor prognosis [79,80]. A selective inhibitor of MMP3 is available (UK370106) but is yet to be tested for
inhibition of primary tumor or metastatic tumor growth [81]. A generic MMP inhibitor is available
(Marimastat, Sigma-Aldrich, St. Louis, MO, USA) [82], but it was not effective in clinical trials [82–85].
In pancreatic small-cell lung cancers trials, it was not established whether the tumours expressed high
levels of MMPs, which could have had implications in establishing drug efficiency [82,85]. Marimastat
has not been tested in OSA. In the present study, it was shown that expression of MMP3 is elevated in
canine osteosarcoma in comparison to non-malignant bone tissue. Selective metalloprotease inhibitors
such as UK370106 and/or marimastat and related candidate drugs may improve the prognosis of
canine OSA in those cases with elevated MMP3 expression. Previously published studies found that
MMP3 was more highly expressed in OSA tumors than in normal bone [86,87], which corroborated the
results found in this study.
Glucose is an essential component in cellular metabolism, with transport into cells reliant on
membrane glycoproteins [88]. SLC2A1 is a gene encoding one such cell membrane glycoprotein,
which has been shown to be involved in glucose transport in a range of tumors including oral
squamous cell carcinoma, non-small cell lung carcinoma, and non-gastrointestinal stromal tumor
soft tissue sarcomas [89–91]. In patients with OSA, higher expression of SLC2A1 within tumors has
been associated with a shorter disease-free interval, and poorer prognosis than in patients with lower
expression of SLC2A1 [92]. In the current study, SLC2A1 expression was significantly higher in OSA
tissue compared to non-tumor tissue. Survival time was not available for patients involved in the
current study, but canine OSA survival time is typically short, up to 14.4 months on average [93]. Based
on the current study results combined with those previously published [92], this could be due to the
high expression of SLC2A1 [10–12]. There are several drugs available that have inhibitory effects on
cellular glucose transport and SLC2A1, but few have been tested as a treatment for OSA [94–97].
A range of cancers have been shown to have aberrant Wnt activity [98–101]. Dickkopf proteins
inhibit Wnt signalling and have been shown to be differentially expressed in colon cancer, prostate cancer,
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and breast cancer [102–104]. Reduced DKK3 expression has been associated with endometrial cancer,
cervical cancer and breast cancer, and as such it has been implicated as a tumor suppressor [99,105–107].
Within OSA there are conflicting reports; in OSA cell lines and xenograft mice, DKK3 expression was
shown to be downregulated, with subsequent restoration of DKK3 expression reducing tumor and
metastatic growth [108]. In contrast, DKK3 has been shown to be more highly expressed in OSA cells
that overexpress NKD2 [109]. The results from the current study showed that DKK3 was more highly
expressed in OSA tissue than in non-tumor tissue. This is in contrast to expression in most other
cancer types, but in agreement with other findings [109]. Knockdown of DKK3 in cells overexpressing
NKD2 increased their proliferative potential indicating that DKK3 expression could be mediating
NKD2-induced metastasis [109]. There are currently no drugs available that act on DKK3. MMP3 and
DKK3 have been shown to have opposite effects on Wnt activation. MMP3 secretion has been shown
to lead to increased Wnt activation [110,111], while increased DKK3 expression results in reduced Wnt
activation [99,105–107]. The results presented in the current study thus appear to contradict these
earlier findings, with both MMP3 and DKK3 expressed more highly in tumor compared to non-tumor
tissue. It is possible that DKK3 is ameliorating the effect of MMP3 secretion in the tumors in this study
in a similar way to the effect identified by Zhao and colleagues [109]. Further work is required to
establish the relationship between MMP3 and DKK3 in OSA.
To assess the functional relevance of the differentially expressed genes identified here,
we performed a comparative search of the KEGG, Panther and Reactome pathway databases using the
WebGestalt platform (www.webgestalt.org; Table 3). By integrating the results obtained from these
complementary databases, the most detailed insight into the mechanistic relevance of the differentially
expressed genes can be obtained. Interestingly, this approach identified aberrant expression of genes
associated with heme biosynthesis. While the exact role of heme in cancer is controversial [112],
aberrant heme metabolism may influence tumor energy metabolism, the tumor microenvironment,
angiogenesis and metastases [112]. Expression of the nine genes (ALAD, ALAS1, COX10, CPOX, FECH,
HMBS, NFE2L1, UROD, UROS) of the heme biosynthesis ontology were lower in OSA as compared
with non-malignant bone. This could be attributed to the loss of normal bone function as bone marrow
is a major source of heme synthesis and hematopoiesis [113]. Bone marrow space may have been
replaced with tumor tissue with a resulting loss in functional marrow. An additional possibility
is that the loss of heme synthesis within the tumor contributes to its progression. There is some
evidence that tetrapyrroles, such as heme, possess anti-cancer properties by inducing apoptosis [114].
Biliverdin and bilirubin, the catalytic products of heme generated by heme oxygenases, have been
shown to have anti-oxidant properties [115]. Due to the reduced expression of genes involved in
tetrapyrrole/heme/pigment metabolic and biosynthetic processes in tumor compared to non-tumor
tissue in this study, it would seem likely that the apoptosis and anti-oxidant properties of tetrapyrroles
is correspondingly reduced.
Pathways associated with calcium signalling and cardiomyopathy (Table 1) involved intracellular
signalling enzymes including integrins, adenylate cyclases 4 and 9, ATPases, and calcium channels,
and indeed calcium homeostasis may reflect aberrant osteoblastic differentiation during osteosarcoma
carcinogenesis [116]. Consistent with this, multiple gene ontologies related to cellular differentiation,
morphogenesis, development, cellular proliferation, and metabolism were associated with the
differentially expressed genes identified here (Table S2).
We used the WebGestalt network module (www.webgestalt.org) to search the human MSigDB
transcription factor target database. This analysis identified 51 transcription factor regulators (Table S3)
predicted to act as regulators of OSA-associated differentially expressed genes (Table S1). Notable
predicted regulators included LEF1, a key regulator of the Wnt/β-catenin pathway, which has
previously been implicated in OSA [117,118]. There were 122 putative LEF1-target genes identified in
the differentially expressed genes. LEF1 expression was significantly different between tumor and
non-tumor tissue (p = 0.0405) with higher expression seen in tumor compared with non-tumor tissue.
Among the genes regulated by LEF1, some demonstrated increased expression in tumor compared
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with non-tumor tissue, whereas others showed decreased expression. Genes do not act in isolation,
therefore, those genes with lower expression in this dataset may have also required the expression of
additional transcription factors or coactivators for activation [119]. LEF1 is associated with increased
Wnt signalling, however, in the current study it appears that genes may be antagonising one another,
with genes that both increase and decrease Wnt signalling expressed more highly in tumor compared
with non-tumor tissue [109–111,120]. Wnt signalling has both canonical and non-canonical pathways,
with non-canonical signalling split into planar cell polarity and Wnt/Ca2+ [121].
Expression of DKK3 and MMP3 are increased in OSA (Figure 2) and both are known to act on
the binding of Wnt activator proteins so alterations in the amount of these proteins will affect both
canonical and non-canonical Wnt signalling [110,121,122]. Combined with the increase in DKK3 and
MMP3 expression seen in tumor tissue, the demonstration of aberrant activation of LEF1 in the current
study adds OSA to the range of cancers that exhibit aberrant Wnt activity [98–101]. LEF1 is part
of the canonical Wnt signalling pathway, requiring β-catenin as a coactivator for downstream gene
transcription [123,124]. It may be that aberrant Wnt processes upstream of LEF1, such as DKK3 and
MMP3 expression, are affecting LEF1 activity. This may explain the difference in the transcription of
genes regulated by LEF1, but not LEF1 itself in OSA tissue compared to non-tumor tissue. LEF1 could
be an additional drug target to influence Wnt signalling within OSA. In addition to association with
CTGF, it has been shown that expression of MMP3 is inversely related to expression of IRF8 [78]. Due to
this, IRF8 could also be an alternative drug target.
In total, 0.53% of all IWHs (n = 379) and 3.04% of Rottweilers (n = 1019) had OSA and although
there were no overall differences in the rates of males and females affected, the males were younger at
diagnosis than females, with a reduction of 2 years and 1.5 years seen for IWH and Rottweiler males,
respectively. It is possible that other factors play a role in this. For example, IWH males are more likely
to die younger from dilated cardiomyopathy and atrial fibrillation than females [125,126]. As heart
disease is the most common specific cause of death in this breed, males may not always live long
enough to develop OSA symptoms/get a diagnosis. The 379 IWHs used in this study were also used in
previous publications to look at population outcomes in cardiomyopathy and atrial fibrillation [126].
The results showed that 65% of the male dogs with dilated cardiomyopathy and/or atrial fibrillation
had been diagnosed before the age of 5.5 years—the average age at which OSA was diagnosed, whereas
only 40% of females had been diagnosed as suffering from these heart diseases at that age [126].
This is the first study to examine the length of the canine NCOA3 polyQ tract. This is also the first
evaluation of the AR polyQ tract in IWHs and Rottweilers. Most individuals had 15 polyQ repeats in
both alleles of the NCOA3 gene, with only one additional repeat in 1% of Rottweiler and 0.5% of IWH
NCOA3 polyQ tracts genotyped. The lack of variation in the length of the NCOA3 polyQ tract in these
two breeds strongly suggests that variation in the length of the NCOA3 polyQ tract is not a contributing
factor in the development of OSA in IWHs, or Rottweilers. The length of the canine AR polyQ tract has
previously been associated with aggression in male Japanese Akita Inus and prostate cancer in a variety
of breeds [127,128]. In the current study, there was no association between the length of the canine AR
and OSA in either IWHs or Rottweilers. Additionally, RNAseq did not identify differential expression
of the AR or NCOA3 in canine OSA relative to non-tumor bone tissue. It was interesting that IWHs
and Rottweilers had significantly different allele frequencies at both AR1 and AR2, which supports
previous findings across other breeds [129]. This difference in allele frequencies may be affected by
different population histories, with founder effects, inbreeding, and genetic hitch-hiking [130–132].
4. Materials and Methods
4.1. Samples and Ethics
This study was approved by the University of Nottingham ethics committee (numbers 1823
160714 and 959 130925, 20 July 2016) in compliance with Home Office regulations and the Veterinary
Surgeons Act. The call for owners to participate in research was made to the public and veterinary
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practices via breed health group collaborations, emails, social media, attending breed shows, and by
holding breed health information days in-house. Informed consent was obtained from all dog owners.
Canine OSA tumor (n = 7) and non-tumor (n = 8) tissue was obtained from veterinary surgeons
following amputation treatment or immediately following euthanasia. Confirmation of OSA was
confirmed by pathologists via histopathological examination. A 1 cm3 piece of tumor was extracted
along with a 1 cm3 piece of adjacent non-tumor affected bone tissue. These samples were placed
directly into RNAlater® (Sigma-Aldrich, St. Louis, MO, USA), shipped at room temperature and stored
at −20 ◦C.
DNA samples from 1019 Rottweilers and 379 IWHs were collected using Isohelix DNA Buccal
Swabs (Cell Projects Ltd., Harrietsham, UK), according to the manufacturer’s instructions. Clinical
histories of each animal were also obtained from owners. Swabs and clinical information were collected
over a 3-year period with regular updates checked for a further 2 years. A Chi-Square (χ2test) was
performed to establish any significant difference in the number of males and females diagnosed with
OSA. In addition, t-tests were performed using R statistical software [133] to compare the mean age
of diagnosis between males and females. From this, appropriate age restrictions for each sex were
established for the inclusion of unaffected individuals in the control group, based on the age by which
most affected individuals had been diagnosed. Individuals in the unaffected group were used in
genetic association testing.
4.2. RNA Extraction and Next Generation Sequencing
OSA tumor (n = 3) and non-tumor (n = 4) bone tissue samples were homogenized (GentleMACS,
Miltenyi Biotec, Bergisch Gladbach, Germany) and RNA extracted using Qiagen RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to manufacturer’s instructions. The extracted RNA was
stored at −80 ◦C. RNA was quantified using both a NanoDrop 8000 (Thermo Fisher Scientific,
Waltham, MA, USA) and an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). RNAseq
analysis of seven samples comprised of four non-malignant bone and three OSA specimens and
was completed at Edinburgh Genomics using an Illumina HiSeq platform (Illumina, San Diego, CA,
USA) with ~20 million reads obtained from all samples analysed. The resultant raw fastq reads
were processed for quality (phred score >30) and adapter sequences removed using Trim Galore
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). The processed raw reads were
aligned to the canine genome (CanFam3.1, https://www.ncbi.nlm.nih.gov/assembly/GCF_000002285.3/)
using the Ensembl annotated iGenomes build using Tophat2 [134]. Differential gene expression analysis
was completed using Cufflinks/Cuffdiff [135] with significantly differentially expressed genes between
the tumor and non-tumor tissue showing a fold change ≥2, and p < 0.05. WebGestalt [136] was also
used to perform comparative gene ontology, KEGG, Panther and Reactome pathway analysis, and
enriched transcription factor target networks to establish insights into the molecular mechanisms of
canine OSA [137,138]. To do this, gene symbols were used to search the human pathway and network
databases accessed via WebGestalt. A subset of these genes was selected for qPCR validation based on
implication in cancer and biological function. RNA sequences in fastq format and gene quantification
values as determined by Cufflinks/Cuffdiff expressed in FRPM have been deposited in the NCBI GEO
database (accession = GSE155646, https://www.ncbi.nlm.nih.gov/geo/).
4.3. Quantitative Reverse Transcriptase PCR
cDNA was generated from the RNA extracted from OSA tumors and associated non-tumor tissue
by reverse transcriptase PCR. The reverse transcriptase PCR reaction mixture consisted of 2 µL of
5× qScript™ cDNA SuperMix (Quanta Biosciences, Beverly, MA, USA), 0.5–1 µg RNA, adjusted to
10 µL using PCR grade H2O. Reverse transcriptase PCR was carried out at 25 ◦C for 5 min followed by
1 h at 42 ◦C. Gene expression of MMP3, MMP2, SLC2A1, DKK3, POSTN, RBP4, ASPN, and S100A8
were quantified using qRT-PCR using TaqMan assays Cf02625966_g1, Cf02649247_g1, Cf02633301_m1,
Cf02633587_m1, Cf02634869_m1, Cf02659289_m1, Cf02655953_m1 respectively, ThermoFisher Scientific,
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Waltham, MA, USA) as described previously [139]. Expression for all samples was normalised to the
internal control Actin (Taqman assays Cf03023880_g1, ThermoFisher Scientific, Waltham, MA, USA)
and relative expression of tumor compared to non-tumor tissue was calculated utilising the methods
described by Pfaffl [140]. t-tests were performed using GraphPad Prism version 7.01 for Windows
(GraphPad Software, La Jolla, CA, USA).
4.4. Immunohistochemistry
Immunohistochemistry was performed to show positive protein expression of a subset of the
genes analysed, SLC2A1, MMP3 and DKK3. Rottweiler post-mortem OSA tissue (n = 16) was obtained
from Bridge Pathology, UK in the form of OSA tissue with neighbouring non-OSA bone. Tissue
was fixed in 4% paraformaldehyde for 2 h, dehydrated through an ethanol series, embedded into
paraffin blocks, and sectioned at 7 µm. Immunohistochemistry was carried out using a Leica Novolink
Polymer Detection Kit (Leica, Wetzlar, Germany) according to manufacturer’s protocols with primary
antibodies diluted in fetal calf serum 1:100; anti-SLC2A1 polyclonal unconjugated rabbit antibody
(100732-TOB-SIB; Stratech, Ely, UK), anti-MMP3 polyclonal unconjugated rabbit antibody (GTX74514;
GeneTex, Irvine, CA, USA), anti-DKK3 (N1C3) polyclonal unconjugated rabbit antibody (GTX100571;
GeneTex, Irvine, CA, USA) were used to stain proteins of interest. Microscopy was carried out to
confirm positive staining cytoplasmic and/or nuclear staining (Leica, Wetzlar, Germany). Negative
controls received no primary antibody and were incubated in fetal calf serum only.
4.5. PolyQ Analysis
DNA extraction was performed as previously described [126]. PCR and fragment length analysis:
The canine AR harbours two polyQ repeat regions within its locus, hereby denoted AR1 and AR2 [129].
AR1 and AR2 were PCR amplified using primers published by Maejima et al. [129]. Primers were
designed to flank the polyQ region of the canine NCOA3 gene. One of each pair of primers was
fluorescently labelled with HEX or 6-FAM dyes (Sigma-Aldrich, St. Louis, MO, USA) to allow fragment
analysis to be carried out (Primers: AR1 forward 6-FAM-CCGTGAGCGCAGCACCTCCCGGTG, reverse
AGGCTGACCGCTGTTGGGAAGGCTGC; AR2 forward 6-FAM-GCCAGCACCACCGGACGAGAATGA,
reverse TAACTGTCCTTGGAGGAGGTGGAAGCA; NCOA3 forward HEX-
CCCAGCAGGGTTTTCTGAATGCCC, reverse CACAGGCCCTGCCAAAACGCCATCC). Pre-PCR
multiplexing, whereby two PCRs are carried out on a sample as a single reaction, was performed
for AR1 and NCOA3 with no discernible effect on PCR efficiency. The reaction mixtures consisted of
1× LightCycler® 480 Probes Master Mix (Roche, Basel, Switzerland), 0.5 µM of primers, and 1.5 µL
of template DNA, with the volume adjusted to 15 µL using PCR grade H2O. The calculation for a
15 µL reaction containing AR1 and NCOA3 primers combined was 7.5 µL 2× Roche Probe Master Mix,
1.5 µL of each primer from a stock with concentration of 5 µM, and 1.5 µL template DNA. AR2 primers
were added to the multiplex post PCR; the calculation for a 15 µL reaction for the AR2 primer pair
was 7.5 µL 2× Roche Probe Master Mix and 1.5 µL of each primer from a stock with concentration
of 5 µM, 3 µL H2O, and 1.5 µL template DNA. The PCR reaction was run for 40 cycles at 94 ◦C for
30 s, annealing temperature for 30 s, and 72 ◦C for 30 s. The optimal annealing temperature was
determined through a temperature gradient PCR, with temperature ranging between 52 ◦C and 64 ◦C.
An annealing temperature of 61 ◦C was used for AR1 and NCOA3, and 57 ◦C was used for AR2.
All multiplex samples were diluted by a factor of 100. Analysis of the fluorescently-labelled PCR
products was undertaken using the Applied Biosystems 3730 DNA Analyzer with GeneScan ROX-500
size standard (DBS Genomics, Durham, UK) for each sample. The size discrepancy between AR1 and
AR2 allowed for discrimination between their FAM-labelled products. Genotypes were scored using
Genemapper software version 3.7 (Applied Biosystems, Foster City, CA, USA). A homozygote of each
allele was Sanger sequenced by Source Bioscience (Source Bioscience, Nottingham, UK) to confirm
correct amplification and the number of polyQ repeats.
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PolyQ statistical analysis: The lengths of AR1 and AR2 were combined to give an overall AR
polyQ repeat tract length. As the AR locus is positioned on the X chromosome, males only have one
copy of the gene while females have two. Therefore, the lengths of AR1 and AR2 were simply summed
for males, while the mean of the summed lengths for both alleles was used for females. For NCOA3,
the mean length of the polyQ tract for both alleles was determined for all individuals. Student’s t-tests
were performed using R statistical software [133] to establish any differences in the length of the polyQ
repeat in AR and NCOA3 between affected and unaffected control groups. The individuals included
in the unaffected groups were established by the age restrictions as determined previously and as
determined in the results. The groups were further split by sex and analysed by ANOVA using R
statistical software [133].
5. Conclusions
Variations in theAR andNCOA3 genes polyQ repeat tracts are not associated with the development
of canine OSA in IWHs and Rottweilers. However, this study has identified several potential therapeutic
targets for improving the outcomes of dogs with OSA. Drugs targeting some of the genes identified
already exist and thus could be rapidly investigated for an effect in OSA. Additional work is required
to determine the functional/mechanistic importance of the difference in expression between tumor and
non-tumor tissue and the potential for utilising spontaneous OSA in dogs to improve understanding
of the disease in people.
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